San Mateo, California–based Cala develops technologies that deliver TAPS (transcutaneous afferent patterned stimulation) therapy. According to the company, its technology enables on-demand, comfortable, at-home therapy for ease of use and management of action hand tremors. This type of tremor occurs when a patient undergoes intentional movement or posture.
Cala currently offers the previous-generation kIQ non-invasive, FDA-cleared, wearable device for action hand tremor relief in those with ET and Parkinson’s. It treats tremor by sensing each patient’s unique tremor signature.
The wrist-worn technology delivers individualized stimulation to the nerves on the wrist that reach the brain to counteract tremor. Cala launched kIQ about a year ago.
kIQ Plus introduces new therapy modes and adaptive calibration to optimize tremor relief and personalize treatment. It provides patients with an intuitive experience whenever they need tremor control.
The company plans to showcase its next-generation wearable at AAN 2026 in Chicago next week.
“Cala continues to elevate the patient experience and therapy outcomes by advancing wearable neuromodulation technology that treats action hand tremor in essential tremor and Parkinson’s disease. The Cala kIQ Plus system gives patients more control over how, when and where TAPS Therapy is delivered for tremor management,” said CEO Deanna Harshbarger. “We will present the latest data on Cala kIQ Plus at the American Academy of Neurology conference in Chicago.”
